Business Context and Reporting Period
Company: Marchex, Inc. (MCHX)
Filing Type: Form 8-K (Current Report)
Date: November 13, 2025
Reporting Period: The filing covers two primary events: the entry into a material definitive agreement dated November 13, 2025, and the issuance of an Earnings Release for the third quarter ended September 30, 2025.
Key Financial Metrics and Transaction Details
Acquisition Transaction (Archenia, Inc.):
- Consideration: $10 million convertible promissory note with 6% interest.
- Payment Terms: Payable in three equal tranches on the 12th, 18th, and 24th monthly anniversaries of the Closing Date.
- Conversion Terms: Principal and interest convertible into Class B common stock at $1.80 per share (based on 30-day average closing price through November 11, 2025).
- Contingent Consideration: Up to 2 million shares of Class B common stock for each of the first two 12-month periods post-closing, subject to Archenia meeting revenue and Adjusted EBITDA thresholds.
Financial Results (Q3 2025):
- The filing references an Earnings Release (Exhibit 99.1) containing specific revenue, profit, cash flow, and margin data for the quarter ended September 30, 2025.
- Note: The specific numerical values for revenue, profit, cash flow, debt, and liquidity are not provided in the text of this 8-K summary; they are contained within the attached Earnings Release.
Material Changes and Transaction Status
Agreement in Principle (AIP): Marchex has entered into an AIP to acquire 100% of Archenia, Inc. This represents a material change in the company's capital structure and strategic direction.
Related Party Transaction: The transaction involves related parties, necessitating approval by a Special Committee of independent directors and a majority of disinterested stockholders.
Timeline: The anticipated Closing Date is in the first half of 2026, pending the negotiation of a Definitive Agreement and satisfaction of conditions.
Guidance, Risks, and Contingencies
Conditions to Closing:
- Receipt of audited financial statements for Archenia.
- Receipt of a customary fairness opinion by a financial advisor selected by the Special Committee.
- Approval by a majority of Marchex's disinterested stockholders.
Risks and Forward-Looking Statements:
- The filing includes standard forward-looking statements regarding the consummation of the transaction, future financial position, and strategy.
- Risks include product demand fluctuations, order cancellations, competition, changes in business strategy, and general economic conditions.
- Actual results may differ materially from expectations.
Non-GAAP Measures: The company utilizes non-GAAP financial measures in its Earnings Release, with reconciliations to GAAP measures provided in Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1: Verify specific Q3 2025 financial results (revenue, net income, cash flow) as they are not detailed in the 8-K text.
- Definitive Agreement Terms: Monitor for the execution of the Definitive Agreement to confirm final purchase price, earn-out thresholds, and closing conditions.
- Stockholder Approval: Confirm the outcome of the vote by disinterested stockholders required to close the Archenia acquisition.
- Related Party Disclosure: Review the specific relationship between the Sellers and Marchex to assess potential conflicts of interest.
- Conversion Impact: Analyze the potential dilution impact of the $10 million note conversion at $1.80 per share and the issuance of up to 4 million contingent shares.